These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21895035)

  • 21. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 22. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 23. Pediatric priorities: legislative and regulatory initiatives to expand research on the use of medicines in pediatric patients.
    Labson MS
    J Health Care Law Policy; 2002; 6(1):34-72. PubMed ID: 15017951
    [No Abstract]   [Full Text] [Related]  

  • 24. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Think about drug packaging.
    Prescrire Int; 2012 Dec; 21(133):284. PubMed ID: 23373090
    [No Abstract]   [Full Text] [Related]  

  • 26. Analysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies.
    Ishibashi T; Kusama M; Sugiyama Y; Ono S
    J Clin Pharm Ther; 2012 Dec; 37(6):657-63. PubMed ID: 22734557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A.
    Wu KM; Dou J; Ghantous H; Chen S; Bigger A; Birnkrant D
    Regul Toxicol Pharmacol; 2010 Feb; 56(1):1-3. PubMed ID: 19782117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary care physicians' use of FDA-approved prescription drug labels.
    Sullivan HW; O'Donoghue AC; Aikin KJ
    J Am Board Fam Med; 2014; 27(5):694-8. PubMed ID: 25201939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of US Food and Drug Administration review intervals for drugs approved during the period 1997-2002.
    Kros JF; Qian J
    Am J Ther; 2004; 11(5):337-43. PubMed ID: 15356429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization of population pharmacokinetics in drug development and provision of the results to healthcare professionals
.
    Watanabe-Uchida M; Narukawa M
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):25-31. PubMed ID: 27841154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labeling.
    Shulman LP; Bateman LH; Creinin MD; Cullins VE; Doyle LL; Godfrey E; Murphy P; Rodriguez P; Spear SJ; Stewart FH; Thomas MA; Westhoff CL; Worthington S
    Contraception; 2006 May; 73(5):440-2. PubMed ID: 16627028
    [No Abstract]   [Full Text] [Related]  

  • 32. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minocycline and Pseudotumor cerebri: The well-known but well-kept secret.
    Weese-Mayer DE; Yang RJ; Mayer JR; Zaparackas Z
    Pediatrics; 2001 Aug; 108(2):519-20. PubMed ID: 11491116
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
    Imatoh T; Sai K; Saito Y
    J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
    Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
    Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006.
    Berendt L; Håkansson C; Bach KF; Dalhoff K; Andreasen PB; Petersen LG; Andersen E; Poulsen HE
    BMJ; 2008 Jan; 336(7634):33-5. PubMed ID: 18063611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
    Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
    Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant differences on submission lag following regulation reform for registration of novel therapeutic drugs in Taiwan.
    Sun IC
    Invest New Drugs; 2019 Oct; 37(5):1094-1106. PubMed ID: 30612310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues.
    Huang SM; Lesko LJ; Williams RL
    J Clin Pharmacol; 1999 Oct; 39(10):1006-14. PubMed ID: 10516934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigational drug labeling variability.
    Duhamel A; Thibault M; Lebel D; Bussières JF; Tanguay C
    Clin Trials; 2019 Apr; 16(2):204-213. PubMed ID: 30714394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.